### ðŸ«€ Cardiology: Anticoagulation for Mechanical Aortic Valve

#### âœ… True Statements
1. Patients with a **mechanical cardiac valve** require **lifelong anticoagulation with warfarin** for thromboembolism prophylaxis.
2. **Direct oral anticoagulants (DOACs)**, including **dabigatran** and **apixaban**, are **contraindicated** in mechanical valves because trials (REâ€‘ALIGN, PROACTÂ Xa) showed excess **bleeding** and **thromboembolic events** compared with warfarin.
3. Anticoagulation for mechanical valves should target a **single international normalized ratio (INR) value**, not a range, and the target depends on valve type and risk factors.
4. For a **mechanical bileaflet or currentâ€‘generation singleâ€‘tilting disc aortic valve** **without additional risk factors** (prior embolism, hypercoagulability, left ventricular dysfunction, or atrial fibrillation), the recommended **target INR isÂ 2.5**.
5. For a **mechanical aortic valve with thromboembolic risk factors**, an **older ballâ€‘inâ€‘cage aortic valve**, or **any mechanical mitral valve**, the recommended **target INR isÂ 3.0**.
6. **Lowâ€‘dose aspirin** is **not routinely added** to warfarin for mechanical valves solely for valve prophylaxis; it may be coâ€‘administered for separate indications (such as **coronary artery disease**) when bleeding risk is low.
7. **Aspirin monotherapy** is inadequate for prevention of valve thrombosis in patients with **mechanical valves** and is reasonable only in patients with a **bioprosthetic valve** who have no other indication for anticoagulation.
8. If the **INR remains persistently above the target**, the **warfarin dosage should be reduced** to lower bleeding risk while preserving thromboembolic protection.
9. During **temporary interruption** of warfarin for **active bleeding** in a patient with a mechanical **aortic valve** **without additional thromboembolic risk factors**, **heparin bridging is unnecessary**.

#### ðŸ’¬ Extra
1. Additional thromboembolic risk factors include a **history of systemic embolization**, **hypercoagulable disorders**, **left ventricular dysfunction**, and **atrial fibrillation**.
2. The shift away from routine aspirin with warfarin is based on evidence that combined therapy increases bleeding without added thromboembolic benefit in most patients with mechanical valves.
3. Warfarin dose adjustment should aim for a **target INR**, recognizing that values above goal markedly increase the risk of **gastrointestinal and intracranial bleeding**.

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #MechanicalValve #Warfarin #Anticoagulation #INR

#### ðŸ“š Reference
Ottoâ€¯CM, Nishimuraâ€¯RA, Bonowâ€¯RO, etâ€¯al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. *Circulation*. 2021;143:e72â€‘e227. PMID:â€¯33332150 doi:10.1161/CIR.0000000000000923

#### ðŸ†” Question ID
CVMCQ24125

#### ðŸ•’ Last Updated
FebruaryÂ 2025

#### ðŸ“– Related Text  
MKSAPÂ 19: CardiovascularÂ Medicine â€” ValvularÂ HeartÂ Disease, ProstheticÂ Valves, ProstheticÂ Valves

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. A **bioprosthetic valve** is preferred in patients of any age who **cannot or do not wish to take warfarin**, despite its limited durability of roughly **15Â years**.
2. Approximately **40% of bioprosthetic valves** implanted in persons **younger thanÂ 60Â years** exhibit clinically severe deterioration by **15Â years** postâ€‘implantation.
3. The **ACC/AHA** considers a **mechanical aortic valve** reasonable in patients **<50Â years**, a **bioprosthesis** reasonable in patients **>65Â years**, and either option acceptable in those aged **50â€“65Â years**.
4. After **mitral valve replacement**, a **mechanical valve** is generally favored in patients **<65Â years**, whereas a **bioprosthesis** is reasonable in those **â‰¥65Â years**.
5. **Echocardiography** should be performed soon after prosthetic valve implantation to establish a **baseline hemodynamic profile** and repeated whenever symptoms or signs of valve dysfunction arise.
6. In patients with a **surgical bioprosthetic valve**, **transthoracic echocardiography (TTE)** is reasonable at **5Â andÂ 10Â years** after surgery and **annually thereafter**, even if asymptomatic.
7. In patients with a **transcatheter bioprosthetic valve**, **annual TTE** is recommended regardless of symptoms.
8. When **TTE** is nondiagnostic for suspected prosthetic valve malfunction, **transesophageal echocardiography (TEE)** should be obtained.
9. **Lifelong warfarin therapy** targeting a specific **INR** is mandatory for **all mechanical valves**, and **DOACs** should not be used because of increased thrombosis risk.
10. For patients with a **bioprosthetic mitral or aortic valve**, shortâ€‘term **warfarin** targeting an **INR ofÂ 2.5** can be considered for **3â€“6Â months after implantation** when bleeding risk is low.
11. **Lowâ€‘dose aspirin (75â€“100â€¯mg/day)** may be added to warfarin in patients with a **mechanical prosthesis** who have other indications for antiplatelet therapy and acceptable bleeding risk.

#### ðŸ’¬ Extra
1. **Valve choice** is influenced by patient age, expected prosthesis durability, surgical reâ€‘operation risk, and willingness to take warfarin.
2. Current data suggest that **transcatheter aortic valve implantation (TAVI)** durability at **8â€“10Â years** is comparable to surgical bioprostheses, but longerâ€‘term data are pending.
3. Decisions between mechanical and bioprosthetic valves should be made through **shared decision making** incorporating patient preferences and comorbidities.

#### ðŸ”· Tags
#ValveChoice #BioprostheticValve #MechanicalValve #Echocardiography #Anticoagulation #Cardiology

---

#### ðŸ§¾ Supplemental Table

<!-- Choice of Valve: Bioprosthetic Versus Mechanical -->
<table>
  <caption>Choice of Valve: Bioprosthetic Versus Mechanical</caption>
  <thead>
    <tr>
      <th>Situation/Age</th>
      <th>AVR<sup>a</sup></th>
      <th>MVR<sup>b</sup></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Unable or unwilling to take VKA</td>
      <td>Bioprosthetic valve</td>
      <td>Bioprosthetic valve</td>
    </tr>
    <!-- Group heading for patients willing/able to take VKA -->
    <tr>
      <td colspan="3"><strong>Willing and able to take VKA</strong></td>
    </tr>
    <tr>
      <td>&nbsp;&nbsp;Age &lt;50&nbsp;years</td>
      <td>Mechanical AVR</td>
      <td>Mechanical MVR</td>
    </tr>
    <tr>
      <td>&nbsp;&nbsp;Age 50â€“65&nbsp;years</td>
      <td>Mechanical or bioprosthetic AVR</td>
      <td>Mechanical MVR</td>
    </tr>
    <tr>
      <td>&nbsp;&nbsp;Age â‰¥65&nbsp;years</td>
      <td>Bioprosthetic AVR</td>
      <td>Bioprosthetic MVR</td>
    </tr>
  </tbody>
</table>
<p>AVR = aortic valve replacement; MVR = mitral valve replacement; VKA = vitamin K antagonist.</p>
<p><sup>a</sup>After consideration of transcatheter aortic valve implantation.</p>
<p><sup>b</sup>If repair is not possible.</p>
